Article Contents ::

Details About Generic Salt ::  Pentosan

Main Medicine Class:: Urinary Analgesic   

(PEN-toe-san)
Elmiron
Class: Urinary Analgesic

 

Action Unknown. Adheres to and may protect the mucosal membrane of the bladder.

 

Indications For relief of bladder pain or discomfort associated with interstitial cystitis.

 

Contraindications Standard considerations.

 

Route/Dosage

ADULTS: PO 100 mg tid.

 

Interactions

Anticoagulants, antiplatelet agents, thrombolytics: Pentosan has weak anticoagulant properties and may potentiate the pharmacological action of other anticoagulants, antiplatelet or thrombolytic drugs.

 

Lab Test Interferences None reported.

 

Adverse Reactions

CNS: Headache; emotional lability; depression; dizziness. DERM: Alopecia; rash. GI: Nausea; abdominal pain; diarrhea; dyspepsia. HEPA: Liver function abnormalities.

 

Precautions

Pregnancy: Category B. Lactation: Unknown. Children: Safety and efficacy not established. Hepatic/Splenic function impairment: Use with caution. Thrombocytopenia: Use with caution in patients with a history of heparin-induced thrombocytopenia. Anticoagulant effects: Since drug has weak anticoagulant effects, carefully evaluate patients with diseases such as aneurysms, thrombocytopenia, hemophilia, GI ulcerations, polyps or diverticula before initiating therapy.

PATIENT CARE CONSIDERATIONS


 

Administration/Storage

  • Administer with water ³ 1 hour before or 2 hours after meals.
  • Store at room temperature (68° to 77°F) in tightly-closed container.

 

Assessment/Interventions

  • Obtain patient history including drug history and any known allergies. Note presence of hepatic or splenic disease or disease which may predispose to bleeding (eg, hemophilia) and history of heparin-induced thrombocytopenia.
  • Monitor patients for signs of bleeding, especially those on anticoagulant or antiplatelet therapy.
  • Assess for pain relief or improvement to help determine effectiveness of treatment.
  • Monitor for adverse reactions and report to physician any notable findings.
OVERDOSAGE: SIGNS & SYMPTOMS
  Unknown. Based on its pharmacology, overdose is likely to manifest as an increased risk of anticoagulation, thrombocytopenia, gastric pain, and liver function abnormalities

 

Patient/Family Education

  • Instruct patient to take as prescribed and not more frequently than directed.
  • Instruct patient to take pentosan polysulfate sodium ³ 1 hour before or 2 hours after meals with a full glass of water.
  • Inform patient of possible adverse reactions with other drugs or foods they may be taking.
  • Advise patient to consult with physician before taking any other medications including otcs.
  • Instruct patient to assess pain relief or improvement and report to the primary care provider ³ q 3 months to determine effectiveness of treatment.
  • Instruct patient to be aware of adverse effects such as bleeding complications (eg, ecchymosis, epistaxis, gum hemorrhage) and alopecia areata. Inform physician if noted.
  • Instruct patient to inform physician if needing invasive dental work, surgery, or other procedures that might expose patient to increased risk for bleeding.
  • Advise the patient to notify primary caregiver if they experience jaundice or other signs of liver disease.
  • Instruct female patients to notify primary care provider if pregnant, planning to become pregnant, or planning to breastfeed.

 

Drugs Class ::

(PEN-toe-san)
Elmiron
Class: Urinary Analgesic

 

Action Unknown. Adheres to and may protect the mucosal membrane of the bladder.

 

Indications For relief of bladder pain or discomfort associated with interstitial cystitis.

 

Contraindications Standard considerations.

 

Route/Dosage

ADULTS: PO 100 mg tid.

 

Interactions

Anticoagulants, antiplatelet agents, thrombolytics: Pentosan has weak anticoagulant properties and may potentiate the pharmacological action of other anticoagulants, antiplatelet or thrombolytic drugs.

 

Lab Test Interferences None reported.

 

Adverse Reactions

CNS: Headache; emotional lability; depression; dizziness. DERM: Alopecia; rash. GI: Nausea; abdominal pain; diarrhea; dyspepsia. HEPA: Liver function abnormalities.

 

Precautions

Pregnancy: Category B. Lactation: Unknown. Children: Safety and efficacy not established. Hepatic/Splenic function impairment: Use with caution. Thrombocytopenia: Use with caution in patients with a history of heparin-induced thrombocytopenia. Anticoagulant effects: Since drug has weak anticoagulant effects, carefully evaluate patients with diseases such as aneurysms, thrombocytopenia, hemophilia, GI ulcerations, polyps or diverticula before initiating therapy.

PATIENT CARE CONSIDERATIONS


 

Administration/Storage

  • Administer with water ³ 1 hour before or 2 hours after meals.
  • Store at room temperature (68° to 77°F) in tightly-closed container.

 

Assessment/Interventions

  • Obtain patient history including drug history and any known allergies. Note presence of hepatic or splenic disease or disease which may predispose to bleeding (eg, hemophilia) and history of heparin-induced thrombocytopenia.
  • Monitor patients for signs of bleeding, especially those on anticoagulant or antiplatelet therapy.
  • Assess for pain relief or improvement to help determine effectiveness of treatment.
  • Monitor for adverse reactions and report to physician any notable findings.
OVERDOSAGE: SIGNS & SYMPTOMS
  Unknown. Based on its pharmacology, overdose is likely to manifest as an increased risk of anticoagulation, thrombocytopenia, gastric pain, and liver function abnormalities

 

Patient/Family Education

  • Instruct patient to take as prescribed and not more frequently than directed.
  • Instruct patient to take pentosan polysulfate sodium ³ 1 hour before or 2 hours after meals with a full glass of water.
  • Inform patient of possible adverse reactions with other drugs or foods they may be taking.
  • Advise patient to consult with physician before taking any other medications including otcs.
  • Instruct patient to assess pain relief or improvement and report to the primary care provider ³ q 3 months to determine effectiveness of treatment.
  • Instruct patient to be aware of adverse effects such as bleeding complications (eg, ecchymosis, epistaxis, gum hemorrhage) and alopecia areata. Inform physician if noted.
  • Instruct patient to inform physician if needing invasive dental work, surgery, or other procedures that might expose patient to increased risk for bleeding.
  • Advise the patient to notify primary caregiver if they experience jaundice or other signs of liver disease.
  • Instruct female patients to notify primary care provider if pregnant, planning to become pregnant, or planning to breastfeed.

Indications for Drugs ::

(PEN-toe-san)
Elmiron
Class: Urinary Analgesic

 

Action Unknown. Adheres to and may protect the mucosal membrane of the bladder.

 

Indications For relief of bladder pain or discomfort associated with interstitial cystitis.

 

Contraindications Standard considerations.

 

Route/Dosage

ADULTS: PO 100 mg tid.

 

Interactions

Anticoagulants, antiplatelet agents, thrombolytics: Pentosan has weak anticoagulant properties and may potentiate the pharmacological action of other anticoagulants, antiplatelet or thrombolytic drugs.

 

Lab Test Interferences None reported.

 

Adverse Reactions

CNS: Headache; emotional lability; depression; dizziness. DERM: Alopecia; rash. GI: Nausea; abdominal pain; diarrhea; dyspepsia. HEPA: Liver function abnormalities.

 

Precautions

Pregnancy: Category B. Lactation: Unknown. Children: Safety and efficacy not established. Hepatic/Splenic function impairment: Use with caution. Thrombocytopenia: Use with caution in patients with a history of heparin-induced thrombocytopenia. Anticoagulant effects: Since drug has weak anticoagulant effects, carefully evaluate patients with diseases such as aneurysms, thrombocytopenia, hemophilia, GI ulcerations, polyps or diverticula before initiating therapy.

PATIENT CARE CONSIDERATIONS


 

Administration/Storage

  • Administer with water ³ 1 hour before or 2 hours after meals.
  • Store at room temperature (68° to 77°F) in tightly-closed container.

 

Assessment/Interventions

  • Obtain patient history including drug history and any known allergies. Note presence of hepatic or splenic disease or disease which may predispose to bleeding (eg, hemophilia) and history of heparin-induced thrombocytopenia.
  • Monitor patients for signs of bleeding, especially those on anticoagulant or antiplatelet therapy.
  • Assess for pain relief or improvement to help determine effectiveness of treatment.
  • Monitor for adverse reactions and report to physician any notable findings.
OVERDOSAGE: SIGNS & SYMPTOMS
  Unknown. Based on its pharmacology, overdose is likely to manifest as an increased risk of anticoagulation, thrombocytopenia, gastric pain, and liver function abnormalities

 

Patient/Family Education

  • Instruct patient to take as prescribed and not more frequently than directed.
  • Instruct patient to take pentosan polysulfate sodium ³ 1 hour before or 2 hours after meals with a full glass of water.
  • Inform patient of possible adverse reactions with other drugs or foods they may be taking.
  • Advise patient to consult with physician before taking any other medications including otcs.
  • Instruct patient to assess pain relief or improvement and report to the primary care provider ³ q 3 months to determine effectiveness of treatment.
  • Instruct patient to be aware of adverse effects such as bleeding complications (eg, ecchymosis, epistaxis, gum hemorrhage) and alopecia areata. Inform physician if noted.
  • Instruct patient to inform physician if needing invasive dental work, surgery, or other procedures that might expose patient to increased risk for bleeding.
  • Advise the patient to notify primary caregiver if they experience jaundice or other signs of liver disease.
  • Instruct female patients to notify primary care provider if pregnant, planning to become pregnant, or planning to breastfeed.

Drug Dose ::

(PEN-toe-san)
Elmiron
Class: Urinary Analgesic

 

Action Unknown. Adheres to and may protect the mucosal membrane of the bladder.

 

Indications For relief of bladder pain or discomfort associated with interstitial cystitis.

 

Contraindications Standard considerations.

 

Route/Dosage

ADULTS: PO 100 mg tid.

 

Interactions

Anticoagulants, antiplatelet agents, thrombolytics: Pentosan has weak anticoagulant properties and may potentiate the pharmacological action of other anticoagulants, antiplatelet or thrombolytic drugs.

 

Lab Test Interferences None reported.

 

Adverse Reactions

CNS: Headache; emotional lability; depression; dizziness. DERM: Alopecia; rash. GI: Nausea; abdominal pain; diarrhea; dyspepsia. HEPA: Liver function abnormalities.

 

Precautions

Pregnancy: Category B. Lactation: Unknown. Children: Safety and efficacy not established. Hepatic/Splenic function impairment: Use with caution. Thrombocytopenia: Use with caution in patients with a history of heparin-induced thrombocytopenia. Anticoagulant effects: Since drug has weak anticoagulant effects, carefully evaluate patients with diseases such as aneurysms, thrombocytopenia, hemophilia, GI ulcerations, polyps or diverticula before initiating therapy.

PATIENT CARE CONSIDERATIONS


 

Administration/Storage

  • Administer with water ³ 1 hour before or 2 hours after meals.
  • Store at room temperature (68° to 77°F) in tightly-closed container.

 

Assessment/Interventions

  • Obtain patient history including drug history and any known allergies. Note presence of hepatic or splenic disease or disease which may predispose to bleeding (eg, hemophilia) and history of heparin-induced thrombocytopenia.
  • Monitor patients for signs of bleeding, especially those on anticoagulant or antiplatelet therapy.
  • Assess for pain relief or improvement to help determine effectiveness of treatment.
  • Monitor for adverse reactions and report to physician any notable findings.
OVERDOSAGE: SIGNS & SYMPTOMS
  Unknown. Based on its pharmacology, overdose is likely to manifest as an increased risk of anticoagulation, thrombocytopenia, gastric pain, and liver function abnormalities

 

Patient/Family Education

  • Instruct patient to take as prescribed and not more frequently than directed.
  • Instruct patient to take pentosan polysulfate sodium ³ 1 hour before or 2 hours after meals with a full glass of water.
  • Inform patient of possible adverse reactions with other drugs or foods they may be taking.
  • Advise patient to consult with physician before taking any other medications including otcs.
  • Instruct patient to assess pain relief or improvement and report to the primary care provider ³ q 3 months to determine effectiveness of treatment.
  • Instruct patient to be aware of adverse effects such as bleeding complications (eg, ecchymosis, epistaxis, gum hemorrhage) and alopecia areata. Inform physician if noted.
  • Instruct patient to inform physician if needing invasive dental work, surgery, or other procedures that might expose patient to increased risk for bleeding.
  • Advise the patient to notify primary caregiver if they experience jaundice or other signs of liver disease.
  • Instruct female patients to notify primary care provider if pregnant, planning to become pregnant, or planning to breastfeed.

Contraindication ::

(PEN-toe-san)
Elmiron
Class: Urinary Analgesic

 

Action Unknown. Adheres to and may protect the mucosal membrane of the bladder.

 

Indications For relief of bladder pain or discomfort associated with interstitial cystitis.

 

Contraindications Standard considerations.

 

Route/Dosage

ADULTS: PO 100 mg tid.

 

Interactions

Anticoagulants, antiplatelet agents, thrombolytics: Pentosan has weak anticoagulant properties and may potentiate the pharmacological action of other anticoagulants, antiplatelet or thrombolytic drugs.

 

Lab Test Interferences None reported.

 

Adverse Reactions

CNS: Headache; emotional lability; depression; dizziness. DERM: Alopecia; rash. GI: Nausea; abdominal pain; diarrhea; dyspepsia. HEPA: Liver function abnormalities.

 

Precautions

Pregnancy: Category B. Lactation: Unknown. Children: Safety and efficacy not established. Hepatic/Splenic function impairment: Use with caution. Thrombocytopenia: Use with caution in patients with a history of heparin-induced thrombocytopenia. Anticoagulant effects: Since drug has weak anticoagulant effects, carefully evaluate patients with diseases such as aneurysms, thrombocytopenia, hemophilia, GI ulcerations, polyps or diverticula before initiating therapy.

PATIENT CARE CONSIDERATIONS


 

Administration/Storage

  • Administer with water ³ 1 hour before or 2 hours after meals.
  • Store at room temperature (68° to 77°F) in tightly-closed container.

 

Assessment/Interventions

  • Obtain patient history including drug history and any known allergies. Note presence of hepatic or splenic disease or disease which may predispose to bleeding (eg, hemophilia) and history of heparin-induced thrombocytopenia.
  • Monitor patients for signs of bleeding, especially those on anticoagulant or antiplatelet therapy.
  • Assess for pain relief or improvement to help determine effectiveness of treatment.
  • Monitor for adverse reactions and report to physician any notable findings.
OVERDOSAGE: SIGNS & SYMPTOMS
  Unknown. Based on its pharmacology, overdose is likely to manifest as an increased risk of anticoagulation, thrombocytopenia, gastric pain, and liver function abnormalities

 

Patient/Family Education

  • Instruct patient to take as prescribed and not more frequently than directed.
  • Instruct patient to take pentosan polysulfate sodium ³ 1 hour before or 2 hours after meals with a full glass of water.
  • Inform patient of possible adverse reactions with other drugs or foods they may be taking.
  • Advise patient to consult with physician before taking any other medications including otcs.
  • Instruct patient to assess pain relief or improvement and report to the primary care provider ³ q 3 months to determine effectiveness of treatment.
  • Instruct patient to be aware of adverse effects such as bleeding complications (eg, ecchymosis, epistaxis, gum hemorrhage) and alopecia areata. Inform physician if noted.
  • Instruct patient to inform physician if needing invasive dental work, surgery, or other procedures that might expose patient to increased risk for bleeding.
  • Advise the patient to notify primary caregiver if they experience jaundice or other signs of liver disease.
  • Instruct female patients to notify primary care provider if pregnant, planning to become pregnant, or planning to breastfeed.

Drug Precautions ::

(PEN-toe-san)
Elmiron
Class: Urinary Analgesic

 

Action Unknown. Adheres to and may protect the mucosal membrane of the bladder.

 

Indications For relief of bladder pain or discomfort associated with interstitial cystitis.

 

Contraindications Standard considerations.

 

Route/Dosage

ADULTS: PO 100 mg tid.

 

Interactions

Anticoagulants, antiplatelet agents, thrombolytics: Pentosan has weak anticoagulant properties and may potentiate the pharmacological action of other anticoagulants, antiplatelet or thrombolytic drugs.

 

Lab Test Interferences None reported.

 

Adverse Reactions

CNS: Headache; emotional lability; depression; dizziness. DERM: Alopecia; rash. GI: Nausea; abdominal pain; diarrhea; dyspepsia. HEPA: Liver function abnormalities.

 

Precautions

Pregnancy: Category B. Lactation: Unknown. Children: Safety and efficacy not established. Hepatic/Splenic function impairment: Use with caution. Thrombocytopenia: Use with caution in patients with a history of heparin-induced thrombocytopenia. Anticoagulant effects: Since drug has weak anticoagulant effects, carefully evaluate patients with diseases such as aneurysms, thrombocytopenia, hemophilia, GI ulcerations, polyps or diverticula before initiating therapy.

PATIENT CARE CONSIDERATIONS


 

Administration/Storage

  • Administer with water ³ 1 hour before or 2 hours after meals.
  • Store at room temperature (68° to 77°F) in tightly-closed container.

 

Assessment/Interventions

  • Obtain patient history including drug history and any known allergies. Note presence of hepatic or splenic disease or disease which may predispose to bleeding (eg, hemophilia) and history of heparin-induced thrombocytopenia.
  • Monitor patients for signs of bleeding, especially those on anticoagulant or antiplatelet therapy.
  • Assess for pain relief or improvement to help determine effectiveness of treatment.
  • Monitor for adverse reactions and report to physician any notable findings.
OVERDOSAGE: SIGNS & SYMPTOMS
  Unknown. Based on its pharmacology, overdose is likely to manifest as an increased risk of anticoagulation, thrombocytopenia, gastric pain, and liver function abnormalities

 

Patient/Family Education

  • Instruct patient to take as prescribed and not more frequently than directed.
  • Instruct patient to take pentosan polysulfate sodium ³ 1 hour before or 2 hours after meals with a full glass of water.
  • Inform patient of possible adverse reactions with other drugs or foods they may be taking.
  • Advise patient to consult with physician before taking any other medications including otcs.
  • Instruct patient to assess pain relief or improvement and report to the primary care provider ³ q 3 months to determine effectiveness of treatment.
  • Instruct patient to be aware of adverse effects such as bleeding complications (eg, ecchymosis, epistaxis, gum hemorrhage) and alopecia areata. Inform physician if noted.
  • Instruct patient to inform physician if needing invasive dental work, surgery, or other procedures that might expose patient to increased risk for bleeding.
  • Advise the patient to notify primary caregiver if they experience jaundice or other signs of liver disease.
  • Instruct female patients to notify primary care provider if pregnant, planning to become pregnant, or planning to breastfeed.

Drug Side Effects ::

(PEN-toe-san)
Elmiron
Class: Urinary Analgesic

 

Action Unknown. Adheres to and may protect the mucosal membrane of the bladder.

 

Indications For relief of bladder pain or discomfort associated with interstitial cystitis.

 

Contraindications Standard considerations.

 

Route/Dosage

ADULTS: PO 100 mg tid.

 

Interactions

Anticoagulants, antiplatelet agents, thrombolytics: Pentosan has weak anticoagulant properties and may potentiate the pharmacological action of other anticoagulants, antiplatelet or thrombolytic drugs.

 

Lab Test Interferences None reported.

 

Adverse Reactions

CNS: Headache; emotional lability; depression; dizziness. DERM: Alopecia; rash. GI: Nausea; abdominal pain; diarrhea; dyspepsia. HEPA: Liver function abnormalities.

 

Precautions

Pregnancy: Category B. Lactation: Unknown. Children: Safety and efficacy not established. Hepatic/Splenic function impairment: Use with caution. Thrombocytopenia: Use with caution in patients with a history of heparin-induced thrombocytopenia. Anticoagulant effects: Since drug has weak anticoagulant effects, carefully evaluate patients with diseases such as aneurysms, thrombocytopenia, hemophilia, GI ulcerations, polyps or diverticula before initiating therapy.

PATIENT CARE CONSIDERATIONS


 

Administration/Storage

  • Administer with water ³ 1 hour before or 2 hours after meals.
  • Store at room temperature (68° to 77°F) in tightly-closed container.

 

Assessment/Interventions

  • Obtain patient history including drug history and any known allergies. Note presence of hepatic or splenic disease or disease which may predispose to bleeding (eg, hemophilia) and history of heparin-induced thrombocytopenia.
  • Monitor patients for signs of bleeding, especially those on anticoagulant or antiplatelet therapy.
  • Assess for pain relief or improvement to help determine effectiveness of treatment.
  • Monitor for adverse reactions and report to physician any notable findings.
OVERDOSAGE: SIGNS & SYMPTOMS
  Unknown. Based on its pharmacology, overdose is likely to manifest as an increased risk of anticoagulation, thrombocytopenia, gastric pain, and liver function abnormalities

 

Patient/Family Education

  • Instruct patient to take as prescribed and not more frequently than directed.
  • Instruct patient to take pentosan polysulfate sodium ³ 1 hour before or 2 hours after meals with a full glass of water.
  • Inform patient of possible adverse reactions with other drugs or foods they may be taking.
  • Advise patient to consult with physician before taking any other medications including otcs.
  • Instruct patient to assess pain relief or improvement and report to the primary care provider ³ q 3 months to determine effectiveness of treatment.
  • Instruct patient to be aware of adverse effects such as bleeding complications (eg, ecchymosis, epistaxis, gum hemorrhage) and alopecia areata. Inform physician if noted.
  • Instruct patient to inform physician if needing invasive dental work, surgery, or other procedures that might expose patient to increased risk for bleeding.
  • Advise the patient to notify primary caregiver if they experience jaundice or other signs of liver disease.
  • Instruct female patients to notify primary care provider if pregnant, planning to become pregnant, or planning to breastfeed.

Drug Mode of Action ::  

(PEN-toe-san)
Elmiron
Class: Urinary Analgesic

 

Action Unknown. Adheres to and may protect the mucosal membrane of the bladder.

 

Indications For relief of bladder pain or discomfort associated with interstitial cystitis.

 

Contraindications Standard considerations.

 

Route/Dosage

ADULTS: PO 100 mg tid.

 

Interactions

Anticoagulants, antiplatelet agents, thrombolytics: Pentosan has weak anticoagulant properties and may potentiate the pharmacological action of other anticoagulants, antiplatelet or thrombolytic drugs.

 

Lab Test Interferences None reported.

 

Adverse Reactions

CNS: Headache; emotional lability; depression; dizziness. DERM: Alopecia; rash. GI: Nausea; abdominal pain; diarrhea; dyspepsia. HEPA: Liver function abnormalities.

 

Precautions

Pregnancy: Category B. Lactation: Unknown. Children: Safety and efficacy not established. Hepatic/Splenic function impairment: Use with caution. Thrombocytopenia: Use with caution in patients with a history of heparin-induced thrombocytopenia. Anticoagulant effects: Since drug has weak anticoagulant effects, carefully evaluate patients with diseases such as aneurysms, thrombocytopenia, hemophilia, GI ulcerations, polyps or diverticula before initiating therapy.

PATIENT CARE CONSIDERATIONS


 

Administration/Storage

  • Administer with water ³ 1 hour before or 2 hours after meals.
  • Store at room temperature (68° to 77°F) in tightly-closed container.

 

Assessment/Interventions

  • Obtain patient history including drug history and any known allergies. Note presence of hepatic or splenic disease or disease which may predispose to bleeding (eg, hemophilia) and history of heparin-induced thrombocytopenia.
  • Monitor patients for signs of bleeding, especially those on anticoagulant or antiplatelet therapy.
  • Assess for pain relief or improvement to help determine effectiveness of treatment.
  • Monitor for adverse reactions and report to physician any notable findings.
OVERDOSAGE: SIGNS & SYMPTOMS
  Unknown. Based on its pharmacology, overdose is likely to manifest as an increased risk of anticoagulation, thrombocytopenia, gastric pain, and liver function abnormalities

 

Patient/Family Education

  • Instruct patient to take as prescribed and not more frequently than directed.
  • Instruct patient to take pentosan polysulfate sodium ³ 1 hour before or 2 hours after meals with a full glass of water.
  • Inform patient of possible adverse reactions with other drugs or foods they may be taking.
  • Advise patient to consult with physician before taking any other medications including otcs.
  • Instruct patient to assess pain relief or improvement and report to the primary care provider ³ q 3 months to determine effectiveness of treatment.
  • Instruct patient to be aware of adverse effects such as bleeding complications (eg, ecchymosis, epistaxis, gum hemorrhage) and alopecia areata. Inform physician if noted.
  • Instruct patient to inform physician if needing invasive dental work, surgery, or other procedures that might expose patient to increased risk for bleeding.
  • Advise the patient to notify primary caregiver if they experience jaundice or other signs of liver disease.
  • Instruct female patients to notify primary care provider if pregnant, planning to become pregnant, or planning to breastfeed.

Drug Interactions ::

(PEN-toe-san)
Elmiron
Class: Urinary Analgesic

 

Action Unknown. Adheres to and may protect the mucosal membrane of the bladder.

 

Indications For relief of bladder pain or discomfort associated with interstitial cystitis.

 

Contraindications Standard considerations.

 

Route/Dosage

ADULTS: PO 100 mg tid.

 

Interactions

Anticoagulants, antiplatelet agents, thrombolytics: Pentosan has weak anticoagulant properties and may potentiate the pharmacological action of other anticoagulants, antiplatelet or thrombolytic drugs.

 

Drug Assesment ::

(PEN-toe-san)
Elmiron
Class: Urinary Analgesic

 

Action Unknown. Adheres to and may protect the mucosal membrane of the bladder.

 

Indications For relief of bladder pain or discomfort associated with interstitial cystitis.

 

Contraindications Standard considerations.

 

Route/Dosage

ADULTS: PO 100 mg tid.

 

Interactions

Anticoagulants, antiplatelet agents, thrombolytics: Pentosan has weak anticoagulant properties and may potentiate the pharmacological action of other anticoagulants, antiplatelet or thrombolytic drugs.

 

Lab Test Interferences None reported.

 

Adverse Reactions

CNS: Headache; emotional lability; depression; dizziness. DERM: Alopecia; rash. GI: Nausea; abdominal pain; diarrhea; dyspepsia. HEPA: Liver function abnormalities.

 

Precautions

Pregnancy: Category B. Lactation: Unknown. Children: Safety and efficacy not established. Hepatic/Splenic function impairment: Use with caution. Thrombocytopenia: Use with caution in patients with a history of heparin-induced thrombocytopenia. Anticoagulant effects: Since drug has weak anticoagulant effects, carefully evaluate patients with diseases such as aneurysms, thrombocytopenia, hemophilia, GI ulcerations, polyps or diverticula before initiating therapy.

PATIENT CARE CONSIDERATIONS


 

Administration/Storage

  • Administer with water ³ 1 hour before or 2 hours after meals.
  • Store at room temperature (68° to 77°F) in tightly-closed container.

 

Assessment/Interventions

  • Obtain patient history including drug history and any known allergies. Note presence of hepatic or splenic disease or disease which may predispose to bleeding (eg, hemophilia) and history of heparin-induced thrombocytopenia.
  • Monitor patients for signs of bleeding, especially those on anticoagulant or antiplatelet therapy.
  • Assess for pain relief or improvement to help determine effectiveness of treatment.
  • Monitor for adverse reactions and report to physician any notable findings.
OVERDOSAGE: SIGNS & SYMPTOMS
  Unknown. Based on its pharmacology, overdose is likely to manifest as an increased risk of anticoagulation, thrombocytopenia, gastric pain, and liver function abnormalities

 

Patient/Family Education

  • Instruct patient to take as prescribed and not more frequently than directed.
  • Instruct patient to take pentosan polysulfate sodium ³ 1 hour before or 2 hours after meals with a full glass of water.
  • Inform patient of possible adverse reactions with other drugs or foods they may be taking.
  • Advise patient to consult with physician before taking any other medications including otcs.
  • Instruct patient to assess pain relief or improvement and report to the primary care provider ³ q 3 months to determine effectiveness of treatment.
  • Instruct patient to be aware of adverse effects such as bleeding complications (eg, ecchymosis, epistaxis, gum hemorrhage) and alopecia areata. Inform physician if noted.
  • Instruct patient to inform physician if needing invasive dental work, surgery, or other procedures that might expose patient to increased risk for bleeding.
  • Advise the patient to notify primary caregiver if they experience jaundice or other signs of liver disease.
  • Instruct female patients to notify primary care provider if pregnant, planning to become pregnant, or planning to breastfeed.

Drug Storage/Management ::

(PEN-toe-san)
Elmiron
Class: Urinary Analgesic

 

Action Unknown. Adheres to and may protect the mucosal membrane of the bladder.

 

Indications For relief of bladder pain or discomfort associated with interstitial cystitis.

 

Contraindications Standard considerations.

 

Route/Dosage

ADULTS: PO 100 mg tid.

 

Interactions

Anticoagulants, antiplatelet agents, thrombolytics: Pentosan has weak anticoagulant properties and may potentiate the pharmacological action of other anticoagulants, antiplatelet or thrombolytic drugs.

 

Lab Test Interferences None reported.

 

Adverse Reactions

CNS: Headache; emotional lability; depression; dizziness. DERM: Alopecia; rash. GI: Nausea; abdominal pain; diarrhea; dyspepsia. HEPA: Liver function abnormalities.

 

Precautions

Pregnancy: Category B. Lactation: Unknown. Children: Safety and efficacy not established. Hepatic/Splenic function impairment: Use with caution. Thrombocytopenia: Use with caution in patients with a history of heparin-induced thrombocytopenia. Anticoagulant effects: Since drug has weak anticoagulant effects, carefully evaluate patients with diseases such as aneurysms, thrombocytopenia, hemophilia, GI ulcerations, polyps or diverticula before initiating therapy.

PATIENT CARE CONSIDERATIONS


 

Administration/Storage

  • Administer with water ³ 1 hour before or 2 hours after meals.
  • Store at room temperature (68° to 77°F) in tightly-closed container.

 

Assessment/Interventions

  • Obtain patient history including drug history and any known allergies. Note presence of hepatic or splenic disease or disease which may predispose to bleeding (eg, hemophilia) and history of heparin-induced thrombocytopenia.
  • Monitor patients for signs of bleeding, especially those on anticoagulant or antiplatelet therapy.
  • Assess for pain relief or improvement to help determine effectiveness of treatment.
  • Monitor for adverse reactions and report to physician any notable findings.
OVERDOSAGE: SIGNS & SYMPTOMS
  Unknown. Based on its pharmacology, overdose is likely to manifest as an increased risk of anticoagulation, thrombocytopenia, gastric pain, and liver function abnormalities

 

Patient/Family Education

  • Instruct patient to take as prescribed and not more frequently than directed.
  • Instruct patient to take pentosan polysulfate sodium ³ 1 hour before or 2 hours after meals with a full glass of water.
  • Inform patient of possible adverse reactions with other drugs or foods they may be taking.
  • Advise patient to consult with physician before taking any other medications including otcs.
  • Instruct patient to assess pain relief or improvement and report to the primary care provider ³ q 3 months to determine effectiveness of treatment.
  • Instruct patient to be aware of adverse effects such as bleeding complications (eg, ecchymosis, epistaxis, gum hemorrhage) and alopecia areata. Inform physician if noted.
  • Instruct patient to inform physician if needing invasive dental work, surgery, or other procedures that might expose patient to increased risk for bleeding.
  • Advise the patient to notify primary caregiver if they experience jaundice or other signs of liver disease.
  • Instruct female patients to notify primary care provider if pregnant, planning to become pregnant, or planning to breastfeed.

Drug Notes ::

(PEN-toe-san)
Elmiron
Class: Urinary Analgesic

 

Action Unknown. Adheres to and may protect the mucosal membrane of the bladder.

 

Indications For relief of bladder pain or discomfort associated with interstitial cystitis.

 

Contraindications Standard considerations.

 

Route/Dosage

ADULTS: PO 100 mg tid.

 

Interactions

Anticoagulants, antiplatelet agents, thrombolytics: Pentosan has weak anticoagulant properties and may potentiate the pharmacological action of other anticoagulants, antiplatelet or thrombolytic drugs.

 

Lab Test Interferences None reported.

 

Adverse Reactions

CNS: Headache; emotional lability; depression; dizziness. DERM: Alopecia; rash. GI: Nausea; abdominal pain; diarrhea; dyspepsia. HEPA: Liver function abnormalities.

 

Precautions

Pregnancy: Category B. Lactation: Unknown. Children: Safety and efficacy not established. Hepatic/Splenic function impairment: Use with caution. Thrombocytopenia: Use with caution in patients with a history of heparin-induced thrombocytopenia. Anticoagulant effects: Since drug has weak anticoagulant effects, carefully evaluate patients with diseases such as aneurysms, thrombocytopenia, hemophilia, GI ulcerations, polyps or diverticula before initiating therapy.

PATIENT CARE CONSIDERATIONS


 

Administration/Storage

  • Administer with water ³ 1 hour before or 2 hours after meals.
  • Store at room temperature (68° to 77°F) in tightly-closed container.

 

Assessment/Interventions

  • Obtain patient history including drug history and any known allergies. Note presence of hepatic or splenic disease or disease which may predispose to bleeding (eg, hemophilia) and history of heparin-induced thrombocytopenia.
  • Monitor patients for signs of bleeding, especially those on anticoagulant or antiplatelet therapy.
  • Assess for pain relief or improvement to help determine effectiveness of treatment.
  • Monitor for adverse reactions and report to physician any notable findings.
OVERDOSAGE: SIGNS & SYMPTOMS
  Unknown. Based on its pharmacology, overdose is likely to manifest as an increased risk of anticoagulation, thrombocytopenia, gastric pain, and liver function abnormalities

 

Patient/Family Education

  • Instruct patient to take as prescribed and not more frequently than directed.
  • Instruct patient to take pentosan polysulfate sodium ³ 1 hour before or 2 hours after meals with a full glass of water.
  • Inform patient of possible adverse reactions with other drugs or foods they may be taking.
  • Advise patient to consult with physician before taking any other medications including otcs.
  • Instruct patient to assess pain relief or improvement and report to the primary care provider ³ q 3 months to determine effectiveness of treatment.
  • Instruct patient to be aware of adverse effects such as bleeding complications (eg, ecchymosis, epistaxis, gum hemorrhage) and alopecia areata. Inform physician if noted.
  • Instruct patient to inform physician if needing invasive dental work, surgery, or other procedures that might expose patient to increased risk for bleeding.
  • Advise the patient to notify primary caregiver if they experience jaundice or other signs of liver disease.
  • Instruct female patients to notify primary care provider if pregnant, planning to become pregnant, or planning to breastfeed.

Disclaimer ::

The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.

We would like to keep you updated with special notifications.